Lupus Anticoagulant Is Associated with Critical Cases and High Mortality in COVID-19: A Literature Review

Overview

Journal Tanaffos

Specialty Pulmonary Medicine

Date 2023 Nov 3

PMID 37920325

Authors

Maral Moafi

Mohammad Javad Ebrahimi

Firouze Hatami

Farid Javandoust Gharehbagh

Arman Ahmadzadeh

Mohammad Mehdi Emam

Alireza Rajaei

Davood Mansouri

Ilad Alavi Darazam

Affiliations

Soon will be listed here.

Abstract

Background: In severe COVID-19 cases, a hypercoagulable state may occur. Antiphospholipid syndrome-related auto-antibodies (APSRAs) contribute to coagulopathy, but their role in COVID- 19 remains unclear. We aimed to investigate the prevalence of positive APSRAs and their effect on clinical outcomes in confirmed COVID-19 patients.

Materials And Methods: In this cross-sectional study, severe hospitalized COVID-19 cases were enrolled. Demographic and clinical data were obtained from the day of admission. APSRAs including IgG and/or IgM anticardiolipin (aCL) and anti-β2-glycoprotein1 (anti-β2GP1) as well as lupus anticoagulant (LAC) were measured.

Results: In this study, 54 severe COVID-19 cases with positive RT-PCR and chest CT scans were recruited. Positive APSRAs were found in 7 (12.9%) patients. Positive LAC was a more prevalent marker as compared to other tests (11.1%). The prevalence of positive aCL (IgM or IgG) and anti-ß2 GPI (IgM or IgG) was 1.8% (in an elderly woman). Lower oxygen saturation was found in the positive APSRAs group as opposed to the negative APSRAs group (70.3±9 vs. 84.8±9.7%). The mortality rate in the positive APSRAs group was significantly higher relative to the negative APSRAs group (83.3% vs. 27.1%; P-value: 0.01). Likewise, the mechanical ventilation requirement in the positive group was also higher (50% vs. 27.1%, P-value: 0.28).

Conclusion: This study indicated that LAC might be associated with critical cases and high mortality of COVID-19. Nonetheless, the mortality was not related to macrothrombotic incidence.

Citing Articles

Persistent Lupus Anticoagulant Positivity and Long-Term Sequelae Following Mild COVID-19.

Kuniyoshi Y Cureus. 2024; 16(10):e72668.

PMID: 39618655 PMC: 11604992. DOI: 10.7759/cureus.72668.

References

Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou M . Characteristics of Patients With Antiphospholipid Antibody Positivity in the APS ACTION International Clinical Database and Repository. Arthritis Care Res (Hoboken). 2020; 74(2):324-335. PMC: 10725727. DOI: 10.1002/acr.24468. View

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J . A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8):727-733. PMC: 7092803. DOI: 10.1056/NEJMoa2001017. View

Lerma L, Chaudhary A, Bryan A, Morishima C, Wener M, Fink S . Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020; 3:100073. PMC: 7691817. DOI: 10.1016/j.jtauto.2020.100073. View

Tang N, Li D, Wang X, Sun Z . Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4):844-847. PMC: 7166509. DOI: 10.1111/jth.14768. View

Pengo V, Tripodi A, Reber G, Rand J, Ortel T, Galli M . Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2009; 7(10):1737-40. DOI: 10.1111/j.1538-7836.2009.03555.x. View

Schouwers S, Delanghe J, Devreese K . Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results?. Thromb Res. 2009; 125(1):102-4. DOI: 10.1016/j.thromres.2009.09.001. View

Madison J, Duarte-Garcia A, Zuo Y, Knight J . Treatment of thrombotic antiphospholipid syndrome in adults and children. Curr Opin Rheumatol. 2020; 32(3):215-227. DOI: 10.1097/BOR.0000000000000702. View

Abdel-Wahab N, Talathi S, Lopez-Olivo M, Suarez-Almazor M . Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus. 2017; 27(4):572-583. DOI: 10.1177/0961203317731532. View

Keeling D, Mackie I, Moore G, Greer I, Greaves M . Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol. 2012; 157(1):47-58. DOI: 10.1111/j.1365-2141.2012.09037.x. View

10.

Zuo Y, Estes S, Ali R, Gandhi A, Yalavarthi S, Shi H . Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020; 12(570). PMC: 7724273. DOI: 10.1126/scitranslmed.abd3876. View

11.

Barbhaiya M, Zuily S, Ahmadzadeh Y, Amigo M, Avcin T, Bertolaccini M . Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care Res (Hoboken). 2020; 73(10):1490-1501. PMC: 8966711. DOI: 10.1002/acr.24520. View

12.

Espinosa G, Zamora-Martinez C, Perez-Isidro A, Neto D, Bravo-Gallego L, Prieto-Gonzalez S . Persistent Antiphospholipid Antibodies Are Not Associated With Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. Front Immunol. 2022; 13:911979. PMC: 9257245. DOI: 10.3389/fimmu.2022.911979. View

13.

Reyes Gil M, Barouqa M, Szymanski J, Gonzalez-Lugo J, Rahman S, Billett H . Assessment of Lupus Anticoagulant Positivity in Patients With Coronavirus Disease 2019 (COVID-19). JAMA Netw Open. 2020; 3(8):e2017539. DOI: 10.1001/jamanetworkopen.2020.17539. View

14.

Ferrari E, Sartre B, Squara F, Contenti J, Occelli C, Lemoel F . High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019. J Am Heart Assoc. 2020; 9(21):e017773. PMC: 7763401. DOI: 10.1161/JAHA.120.017773. View

15.

Siguret V, Voicu S, Neuwirth M, Delrue M, Gayat E, Stepanian A . Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. Thromb Res. 2020; 195:74-76. PMC: 7342042. DOI: 10.1016/j.thromres.2020.07.016. View

16.

Xiao M, Zhang Y, Zhang S, Qin X, Xia P, Cao W . Antiphospholipid Antibodies in Critically Ill Patients With COVID-19. Arthritis Rheumatol. 2020; 72(12):1998-2004. PMC: 7361932. DOI: 10.1002/art.41425. View

17.

Gutierrez Lopez de Ocariz X, Quismondo N, Vera Guerrero E, Rodriguez Rodriguez M, Diaz R, Lopez J . Thrombosis and antiphospholipid antibodies in patients with SARS-COV-2 infection (COVID-19). Int J Lab Hematol. 2020; 42(6):e280-e282. PMC: 7461094. DOI: 10.1111/ijlh.13320. View

18.

Castro C, Gourley M . Diagnostic testing and interpretation of tests for autoimmunity. J Allergy Clin Immunol. 2010; 125(2 Suppl 2):S238-47. PMC: 2832720. DOI: 10.1016/j.jaci.2009.09.041. View

19.

Satta N, Kruithof E, Fickentscher C, Dunoyer-Geindre S, Boehlen F, Reber G . Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood. 2011; 117(20):5523-31. DOI: 10.1182/blood-2010-11-316158. View

20.

Asherson R, Cervera R . Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003; 62(5):388-93. PMC: 1754545. DOI: 10.1136/ard.62.5.388. View